Chin-Hsuan ShenYi-Sun YangIrene Tai-Lin LeeMeng-Han ChiangSteven T ChenKevin Sheng-Kai Ma2026-02-042026-02-042024-05-2910.1093/bjd/ljae229https://scholars.csmu.edu.tw/handle/123456789/5006<jats:p>Treatment with sodium–glucose cotransporter-2 inhibitors (SGLT2i) is associated with a decreased risk of new-onset inflammatory skin diseases, including vitiligo, acne vulgaris, rosacea and urticaria in patients with diabetes. Prospective studies and clinical trials are warranted to validate the safety and efficacy of SGLT2i in patients with diabetes and concomitant inflammatory skin diseases.</jats:p>[SDGs]SDG3Sodium–glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseasesjournal-article